In April 2015, five patients with metastatic lung cancer sat together in a Washington DC bar and shared their longing for a cure. Of the 175 patients attending the LUNGevity Hope Summit, they were the only ones with cancer driven by ROS1 gene fusions (ROS1-positive cancer). They were all receiving the same experimental targeted therapy and knew their cancer would eventually progress. After that, their only treatment option was chemotherapy, which typically has considerable adverse effects.
Currently, about 30% of patients with non-small-cell lung cancer (NSCLC) have tumours that test positive for an oncogenic driver that makes them eligible for treatment with approved targeted therapies 1 . Specifically, targeted therapies can provide patients with NSCLC harbouring mutations in EGFR, ALK, ROS1, NTRK1-3 or BRAF with months or even years of additional survival, with a good quality of life. With other targeted therapies lurking around the corner for RET, MET or KRAS oncogene-driven NSCLC, we expect the fraction of NSCLCs that are manageable with such agents to reach almost 50%. These drugs offer no cure, however; the cancer inevitably develops resistance. ROS1-positive NSCLC accounts for only ~1% of NSCLCs and is being studied by just a handful of researchers. Many oncologists can't keep completely up to date with the rapidly evolving NSCLC treatment guidelines or clinical trial options; most have never even met a patient with ROS1-positive disease.
That day in April, the five patients decided to take action. They founded The ROS1ders, an international support and advocacy group for patients and caregivers dealing with all types of ROS1-positive cancers.
Today, The ROS1ders is a thriving community centred around a private Facebook group comprising >500 patients and caregivers dealing with ROS1-positive cancer in 36 countries -more patients than any published ROS1-positive cohort. Eight different cancers (including melanoma and pancreatic cancer) are represented in the group to date, though most patient members have NSCLC. The members of this community strive to improve the outcomes of all patients with ROS1-positive cancer by supporting patients and caregivers, increasing awareness and education, accelerating research and improving access to effective diagnosis and treatment. They are recognized as experts on their own disease and valued as partners by researchers, clinicians, non-profit organizations dedicated to lung cancer and government agencies [2] [3] [4] . Herein, we highlight the achievements of The ROS1ders as well as other oncogene-focused patient groups that have become active partners in lung cancer research over the past 4 years.
Several oncogene-focused patient groups have now been formed on Facebook, including all of those mentioned herein. These groups provide a forum for members to share what they learn from expert clinicians and researchers, as well as their personal experiences. To promote trust and transparency, emphasis is placed on citing reliable sources when sharing medical information. Group administrators strive to ensure the information provided is accurate, and consult physician partners when questions go beyond the personal experiences of the group. New members join these groups because they want to survive (or help a loved-one do so), and realize their best chance is to learn as much as possible about their disease. In our experience, empowered, educated and engaged patients have better outcomes than generally expected.
Some patient groups also make information publicly available on websites and social media outlets, such as Twitter. For instance, The ROS1ders website offers information on treatment options, names of expert clinicians, lists of clinical trials, research and advocacy news, and resources for patients and caregivers. The groups also provide research and clinical updates via webinars and video interviews with partners 5 . In exchange, the groups help their research partners expand their reach in disseminating accurate and reliable information, as well as providing access to real world data from a large cohort of patients, input on study design and assistance in trial recruitment.
Simply talking is not enough, however. These groups want to accelerate research into their respective cancers. The groups partner as equals to initiate patient-driven
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As more patients with oncogene-driven non-small-cell lung cancer are treated with targeted therapies, they are joining forces online to form groups that provide support, education and advocacy focused on specific oncogenes. Herein, we discuss how the involvement of these groups in patient-partnered research can benefit both patients and lung cancer research.
The ROS1ders, Inc., Mountain View, CA, USA. *e-mail: ros1cancer.patient@ gmail.com research, and aim to ensure that patients are included in all aspects of the project and retain control of their own data, whilst promoting open data policies. Each oncogene-dedicated patient group has unique needs and research priorities. The ROS1ders are championing the ROS1 Cancer Model Project, which consists of two arms focused on generating ROS1-positive cancer models (both cell lines and patient-derived xenograft mice) from either fresh tumour tissue or pleural fluid donated by North American ROS1ders after medically necessary procedures 6 . So far, this project has resulted in creation and/or genomic characterization of eight new ROS1 cells lines that have been shared with five organizations and used in three peer-reviewed publications 7-9 with a focus on characterizing tumour biology, investigating resistance mechanisms and developing better biomarker tests and treatments. European ROS1ders have also initiated a cell line project in the Netherlands. An informal survey within The ROS1ders group also provided the impetus for a now-published study about the frequency of brain metastases in ROS1-positive NSCLC 10 . Beyond the ROS1ders, the EGFR Resisters group is partnering in Project PRIORITY in order to capture the real-world diagnostic and treatment experiences of patients living with EGFR-mutant NSCLC, with initial findings presented at the 2019 World Conference on Lung Cancer 11 . ALK Positive is funding three research projects focused on immunotherapy for ALK-rearranged NSCLC 12 . The Exon 20 Group provides patients with free molecular tumour board consults and navigation services to help patients with EGFR or HER2 (ERBB2) exon 20 mutations access relevant clinical trials. Some of the groups are also exploring ways to participate in data repositories that store surveys, clinical records and genomic information from analyses of biopsy samples.
While patient groups have many ideas for projects, the rarity and urgency of our diseases forces us to focus. Our biggest challenges are ensuring sustainability and engaging new volunteers -volunteering is not a top priority for most people actively dealing with advanced-stage cancer.
Researchers, clinicians, advocacy groups and the biotech and pharmaceutical industries can help improve outcomes for patients with oncogene-driven cancers by partnering with patient groups. These partners can help groups like the ROS1ders grow and become sustainable; provide accurate and timely information about biomarker testing, therapeutic options and clinical trials; develop patient-driven research studies and savvy research advocates; and ensure access to optimal diagnostic pathways, treatment and care. We believe that through collaboration, all stakeholders in the lung cancer community will benefit -especially the patients.
